Impact of schistosomiasis on patient and graft outcome after renal transplantation: 10 years' follow-up

TitleImpact of schistosomiasis on patient and graft outcome after renal transplantation: 10 years' follow-up
Publication TypeJournal Article
Year of Publication2001
AuthorsMahmoud KM, Sobh MA, El-Agroudy AE, Mostafa FE, Baz ME, Shokeir AA, Ghoneim MA
JournalNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Pagination2214 - 2221
Date PublishedNov
ISSN0931-0509; 0931-0509
Accession NumberPMID: 11682670
KeywordsAdult, Anthelmintics / therapeutic use, Female, Follow-Up Studies, Humans, Kidney Failure, Chronic / etiology / surgery, Kidney Transplantation / adverse effects, Male, Oxamniquine / therapeutic use, Praziquantel / therapeutic use, Risk Factors, Schistosomiasis / complications / drug therapy / physiopathology, Schistosomicides / therapeutic use, Treatment Outcome, Urinary Tract Infections / etiology

BACKGROUND: Schistosomiasis is a major health problem in some areas of the world. Schistosomal-specific nephropathy is a well-known occurrence and eventually leads to end-stage renal failure. Patients with schistosomal infection were considered to be suitable recipients for renal transplantation. However, the long-term impact of schistosomiasis on kidney transplantation is not yet been reported. METHODS: The long-term impact of schistosomiasis on patient and graft outcomes was studied by comparing two groups of subjects from a total of 243 patients. Group I consisted of cases with schistosomal infections and group II consisted of schistosoma-free controls. Schistosomiasis was documented in group I by identifying schistosoma eggs in urine, stool or rectal mucosal biopsy. Also intra-operative biopsies from bladder mucosa of the graft recipients and from the lower end of the ureter of living donors were obtained to search for schistosoma eggs. RESULTS: Sixty-three cases of schistosomiasis were diagnosed in both recipients and donors, 65 cases in recipients only, and eight cases in donors only. Infected recipients and donors with active lesions were treated at least 1 month before transplantation by combined antischistosomal drugs (praziquantel and oxamniquine). The 243 patients (136 schistosoma-infected cases and 107 controls) were followed regularly for a period of 10 years after transplantation. We found that there was no significant difference in the incidence of acute and chronic rejection between the groups; however, higher cyclosporin doses were needed for the infected group with subsequent higher incidence of both acute and chronic cyclosporin nephrotoxicity. Moreover, the schistosomal group had a significantly higher incidence of urinary tract infection and urological complications with no evidence of schistosomal re-infection. CONCLUSIONS: Despite a higher incidence of schistosoma-related complications after renal transplantation, schistosomal infection is not a major risk factor for transplantation. Therefore, infected patients can be considered as suitable recipients if they have been properly treated before transplantation.

Alternate JournalNephrol.Dial.Transplant.
Notify Library Reference ID1719

Related Incidents